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Limitations in the Effect of Screening on Breast
Cancer Mortality
Anna-Belle Beau, Per Kragh Andersen, Ilse Vejborg, and Elsebeth Lynge
A B S T R A C T
Purpose
Randomized, controlled trials showed that screening reduces breast cancer mortality rates, but
some recent observational studies have concluded that programmatic screening has had minor
effect on breast cancer mortality rates. This apparent contradiction might be explained by the use of
aggregated data in observational studies. We assessed the long-term effect of screening using
individual-level data.
Materials and Methods
Using data from mammography screening in the Copenhagen and Danish national registers,
we compared the observed breast cancer mortality rate in women invited to screening with
the expected rate in absence of screening. The effect was examined using the “naı¨ve model,”
which included all breast cancer deaths; the “follow-up model,” which counted only breast
cancer deaths in women diagnosed after their ﬁrst invitation to screening; and the “evaluation
model,” which is similar to the follow-up model during screening age, but after screening age,
which counted only breast cancer deaths and person-years in women diagnosed during
screening age.
Results
We included 18,781,292 person-years, 976,743 of which were from women invited to screening.
The naı¨ve and follow-up models showed, respectively, 10% and 11% reduction in breast cancer
mortality after invitation to screening. However, many breast cancer deaths occurred in women
whose cancer was diagnosed when they were no longer eligible for screening. Accounting for this
dilution, the evaluation model showed a 20% (95% CI, 10% to 29%) reduction in breast cancer
mortality after invitation to screening.
Conclusion
Screening had a clear long-term beneﬁcial effect with a 20% reduction in breast cancer–associated
mortality in the invited population. However, this effect was, by nature, restricted to breast cancer
deaths in women who could potentially beneﬁt from screening. Our study highlights the complexity
in evaluating the long-term effect of breast cancer screening from observational data.
J Clin Oncol 36:2988-2994. © 2018 by American Society of Clinical Oncology. Licensed under the
Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/
INTRODUCTION
Breast cancer screening’s primary aim is to reduce
the rate of breast cancer mortality. In the 1980s,
several randomized controlled trials, ﬁrst from
Sweden, showed that screening with mammog-
raphy only could help reduce breast cancer
mortality rates.1 In one recent review, the com-
bined evidence from the randomized controlled
trials showed that screening delivered about
a 20% reduction in breast cancer mortality rate2;
another review found that screening reduced the
mortality rate associated with breast cancer by an
average of 25%3; and another found there was
a mortality reduction across all ages varying from
12% in women aged 39 to 49 years, 14% in
women aged 50 to 59 years, 33% in women aged
60 to 69 years, and 20% in women aged 70 to 74
years.4
On this background, screening has been
widely implemented in routine health care.
Nevertheless, breast cancer screening is one of
the most intensively debated health care in-
terventions. During the same period that
screening was introduced, breast cancer treat-
ment improved, which makes it difﬁcult to
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separate the effect of screening from the effect of treatment. To
address this problem, modeling studies based on US data
concluded that both screening and treatment helped reduce the
rate of death from breast cancer.5
Recent studies have focused on the incidence of late-stage
breast cancer. The underlying assumption was that the effect of
screening should result in a decrease in the incidence of late-stage
breast cancer. If not observed, a decline in the breast cancer
mortality rate would be attributable to treatment and not to
screening. A study from the United States concluded that “the
reduction in breast cancer mortality after the implementation of
screening was predominantly the result of improved systemic
therapy,”6 and another study, using Dutch data, concluded that the
“screening programwould have had little inﬂuence on the decrease
in breast cancer mortality.”7 These studies analyzed data for all
women above screening age, which is 40 years in the United States
and 50 years in the Netherlands. However, not all women in these
road age groups could have been affected by screening, and such
studies, therefore, cannot correctly capture the possible effect of
screening. For a proper evaluation of screening, it is necessary to
avoid the use of broad age groups, to focus instead on the actual
birth cohorts of women potentially affected by screening, and to
use individual records instead of aggregated data.
In this study, we used individual-level data to analyze the
long-term effect on breast cancer mortality rates of a population-
based breast cancer screening program in Copenhagen,
Denmark.
MATERIALS AND METHODS
Breast Cancer Screening Program
The Copenhagen screening program started with biennial screening
on April 1, 1991. Women aged 50 to 69 years were invited every second year
to screening. Other regional, organized programs were implemented in
Funen in 1993, in Frederiksberg in 1994, in Bornholm in 2001, and in part
of Vestsjælland in 2004. Nationwide, organized screening in Denmark
started at the end of 2007 and early 2008.
Study Participants
Contemporary groups (screening period). The Copenhagen study
group included women invited to screening in the Copenhagen program
between April 1, 1991 and December 31, 2007. The regional control group
included women living in a nonscreening region (the rest of Denmark
excluding Copenhagen, Funen, Frederiksberg, Bornholm, and Vestsjæl-
land) during the same period. In the regional control group, a ﬁrst pseudo-
invitation date was allocated to each woman following the scheme similar
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to that of the Copenhagen study group. Contemporary groups are illus-
trated in the Lexis diagram (Fig 1).
Historical control groups (before screening). The historical Copen-
hagen control group included women living in Copenhagen between April
1, 1977 and March 31, 1991. The historical, regional control group
included women living in a nonscreening region during the same period.
For both groups, ﬁrst pseudo-invitation dates were allocated similarly
to the procedure used for the regional control group. The construction
of the groups is detailed in Data Supplement.
Using data from mammography screening in Copenhagen and
Danish national registers,8-10 we compared the observed breast cancer
mortality rate in women invited to screening with the expected rate in
absence of screening.11,12 Data sources and the statistical analysis are
described in the Data Supplement.
The Na¨ıve Model
The naı¨ve model included all breast cancer deaths occurring during
the follow-up period (thus disregarding date of diagnosis and assuming
that all breast cancer cases contributed to breast cancer deaths, even the
cases diagnosed before ﬁrst [or pseudo] date of invitation to screening).
Person-years were accumulated from date of invitation (or pseudo-
invitation) until date of death, emigration, or end of follow-up,
whichever occurred ﬁrst. However, many breast cancer cases would be
diagnosed before the woman had been invited to screening. Thus, in the
naı¨ve model, the reduction in breast cancer mortality rate is diluted by
breast cancer deaths occurring in patients who could not have beneﬁted
from screening.
The Follow-Up Model
The follow-up model, as described by Nystro¨m et al,13 included only
breast cancer deaths derived from breast cancer cases diagnosed after the
ﬁrst/pseudo-invitation to screening. Person-years were accumulated from
date of invitation (or pseudo-invitation) until date of death, emigration, or
end of follow-up, whichever occurred ﬁrst. However, in this model,
a nonnegligible proportion of breast cancer deaths would derive from cases
diagnosed after the women had left screening. Thus, the effect of screening
is diluted by breast cancer deaths occurring in patients diagnosed after
screening age.14,15
The Evaluation Model
Another approach to avoid the dilution phenomenon is to evaluate
the effect of screening only among breast cancer cases diagnosed during
the screening period. We estimated a modiﬁed version of the evaluation
model developed by Nystro¨m et al.13 We included breast cancer deaths
occurring among women who received a breast cancer diagnosis during
the screening period (ie, during the screening age plus 6 months, to allow
time for diagnosis) and equivalent for the control groups. Accordingly,
we ensured that only breast cancer deaths that could potentially be
affected by screening were counted. For women of screening age, person-
years were accumulated from date of invitation (or pseudo-invitation)
until date of death, emigration, or end of follow-up, whichever occurred
ﬁrst. For women after screening age, person-years were accumulated
only among women with breast cancer diagnosed during the screening
period. In doing so, we ensured that only the women at risk for de-
veloping the event according to our deﬁnition contributed person-years
in the analysis. Until end of screening age, the follow-up and the
evaluation models were identical, but the two models differed after end
of screening age. There are no empirical data to unambiguously ﬁll the
gap between these two models.
Analyses were conducted using SAS, version 9.4 (SAS Institute, Cary,
NC). The study was approved by the Danish Data Protection Agency (No.
2015-57-0121).
RESULTS
The study was based on 18,781,292 person-years of data, among
which 976,743 were from women invited to screening and
17,804,549 were from control subjects. The individual average
follow-up time from invitation (or pseudo-invitation) to end of
follow-up was 11.6 years. The mean age at ﬁrst/pseudo-invitation
was 56.9 years.
The Na¨ıve Model
The crude breast cancer mortality rate in the Copenhagen
study group was 130.0 per 100,000 person-years, compared with
148.2 per 100,000 person-years estimated in the absence of
screening. The age-adjusted rate ratio was 0.90 (95% CI, 0.84 to
0.97; Data Supplement).
The Follow-Up Model
Figure 1 illustrates the dilution phenomenon. Across all ages,
only 67% of breast cancer deaths expected after ﬁrst invitation to
screening in the study group occurred among women diagnosed
with breast cancer after screening started; in the age group 50 to 54
years, the percentage was only 23%.
The crude breast cancer mortality rate in the Copenhagen
study group was 85.4 per 100,000 person-years, compared with
100.7 per 100,000 person-years estimated in the absence of
screening. The age-adjusted rate ratio was 0.89 (95% CI, 0.82 to
0.98; Table 1).
The Evaluation Model
As the length of follow-up after screening age increased, the
amount of dilution by breast cancer deaths among cases diagnosed
after the last screen increased. Overall, only 43% of breast cancer
deaths expected after ﬁrst invitation to screening in the study
group occurred among women diagnosed when eligible for
screening (Fig 2).
The number of breast cancer deaths and accumulated person-
years decreased from age $ 70 years. The crude breast cancer
mortality rate in the Copenhagen study groupwas 73.2 per 100,000
person-years as compared with 93.0 per 100,000 person-years
expected in the absence of screening. This resulted in a re-
duction in breast cancer mortality after invitation to screening. The
age-adjusted rate ratio was 0.80 (95% CI, 0.71 to 0.90; Table 1).
In the naı¨ve and follow-up models, the effect of screening was
restricted to the screening age; there also was a marked effect of
screening after the end of the screening age in the evaluation model
(Fig 3).
DISCUSSION
We conducted a population-based study using individual records
investigating the long-term impact of breast cancer screening on
breast cancer mortality rates. According to our study data, a sub-
stantial proportion of breast cancer deaths were among women
whose breast cancer was diagnosed when the women were no
longer eligible for screening. Inclusion of these breast cancer deaths
2990 © 2018 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Beau et al
Downloaded from ascopubs.org by Royal Library on November 9, 2018 from 130.225.098.216
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
Ta
bl
e
1.
B
re
as
t
C
an
ce
r
D
ea
th
s,
P
er
so
n-
Y
ea
rs
,
B
re
as
t
C
an
ce
r
M
or
ta
lit
y
R
at
es
,
an
d
R
at
e
R
at
io
E
st
im
at
e
of
th
e
C
op
en
ha
ge
n
M
am
m
og
ra
ph
y
S
cr
ee
ni
ng
P
ro
gr
am
A
ge
G
ro
up
N
o.
of
B
re
as
t
C
an
ce
r
D
ea
th
s/
P
Y
pe
r
1,
00
0/
R
at
e
pe
r
10
0,
00
0
P
Y
E
xp
ec
te
d
R
at
e
in
th
e
A
bs
en
ce
of
S
cr
ee
ni
ng
*
S
cr
ee
ni
ng
E
ff
ec
t†
,
C
ru
de
ra
te
ra
tio
(9
5%
C
I)
C
op
en
ha
ge
n
S
tu
dy
R
es
t
D
K
C
op
en
ha
ge
n,
H
is
to
ric
al
R
es
t
D
K
,
H
is
to
ric
al
50
-5
4
14
/1
11
/1
2.
6
13
4/
1,
20
9/
11
.1
32
/9
0/
35
.7
13
5/
75
5/
17
.9
22
.1
0.
57
(0
.2
9
to
1.
12
)
55
-5
9
75
/1
84
/4
0.
7
79
4/
1,
93
5/
41
.0
90
/1
88
/4
7.
9
62
9/
1,
26
8/
49
.6
39
.6
1.
03
(0
.7
4
to
1.
42
)
60
-6
4
98
/1
64
/5
9.
8
1,
03
1/
1,
63
3/
63
.1
15
0/
22
7/
66
.0
78
2/
1,
20
8/
64
.7
64
.4
0.
93
(0
.7
1
to
1.
22
)
65
-6
9
10
3/
14
9/
69
.0
1,
12
2/
1,
38
2/
81
.2
20
2/
25
0/
80
.7
80
8/
1,
10
6/
73
.0
89
.8
0.
77
(0
.6
0
to
0.
99
)
Fo
llo
w
-u
p
m
od
el
E
va
lu
at
io
n
m
od
el
Fo
llo
w
-u
p
m
od
el
E
va
lu
at
io
n
m
od
el
Fo
llo
w
-u
p
m
od
el
E
va
lu
at
io
n
m
od
el
Fo
llo
w
-u
p
m
od
el
E
va
lu
at
io
n
m
od
el
Fo
llo
w
-u
p
m
od
el
E
va
lu
at
io
n
m
od
el
Fo
llo
w
-u
p
m
od
el
E
va
lu
at
io
n
m
od
el
70
-7
4
14
6
11
7
1,
38
4
1,
07
7
31
0
24
4
97
5
74
8
13
7.
9
25
5.
3
0.
70
(0
.5
7
to
0.
87
)
0.
68
(0
.5
3
to
0.
86
)
15
1
68
1,
30
2
54
3
25
6
11
6
1,
04
6
45
7
96
.9
17
3.
2
10
6.
3
19
8.
4
12
0.
9
21
0.
5
93
.2
16
3.
6
75
-7
9
18
5
63
1,
42
9
48
6
31
3
98
12
06
36
9
14
5.
5
2,
67
4.
1
1.
06
(0
.8
7
to
1.
29
)
0.
78
(0
.5
5
to
1.
10
)
12
0
3
1,
06
6
21
21
4
2
89
2
9
15
3.
8
2,
07
7.
3
13
4.
1
2,
32
1.
5
14
6.
6
4,
93
0.
9
13
5.
1
4,
28
0.
8
80
-8
4
13
0
20
1,
04
9
16
7
27
7
31
99
8
14
0
20
6.
5
2,
12
2.
9
0.
94
(0
.7
5
to
1.
18
)
0.
73
(0
.4
0
to
1.
34
)
67
1
58
7
8
13
0
1
54
2
4
19
4.
1
1,
55
8.
4
17
8.
6
2,
09
5.
7
21
2.
7
3,
63
3.
3
18
4
3,
58
6.
7
85
-8
9
70
8
54
1
36
13
3
8
51
2
26
25
7.
7
2,
48
0.
6
1.
04
(0
.7
6
to
1.
42
)
0.
84
(0
.2
8
to
2.
53
)
26
,
1
22
3
2
47
,
1
18
9
1
26
4.
4
2,
08
8.
3
24
2.
4
1,
93
5.
5
28
4.
7
3,
69
0.
5
27
0.
9
2,
87
9.
5
90
-9
4
13
0
97
1
16
0
64
3
31
5.
2
—
1.
06
(0
.4
8
to
2.
35
)
—
4
,
1
29
,
1
6
,
1
22
,
1
33
4
—
33
2.
6
62
8.
2
27
9.
3
—
29
4.
7
4,
26
9.
3
50
-9
4
83
4
49
8
7,
58
1
4,
84
8
1,
52
3
85
5
6,
10
9
3,
64
0
10
0.
7
93
.0
0.
85
(0
.7
7
to
0.
93
)
0.
79
(0
.7
0
to
0.
88
)
A
ge
-a
dj
us
te
d
ra
te
ra
tio
(9
5%
C
I)
97
7
68
1
9,
36
6
6,
73
3
1,
40
7
87
4
7,
03
1
4,
80
9
0.
89
‡
(0
.8
2
to
0.
98
)
0.
80
‡
(0
.7
1
to
0.
90
)
85
.4
73
.2
80
.9
72
.0
10
8.
2
97
.8
86
.9
75
.7
N
O
TE
.
Fo
r
ca
lc
ul
at
io
ns
,
se
e
M
et
ho
ds
,
S
ta
tis
tic
al
an
al
ys
is
.
A
bb
re
vi
at
io
ns
:
—
,
no
da
ta
;
C
I,
co
nﬁ
de
nc
e
in
te
rv
al
;
D
K
,
D
en
m
ar
k;
P
Y
,
pe
rs
on
-y
ea
rs
;
R
es
t
D
K
,
re
gi
on
s
w
ith
ou
t
sc
re
en
in
g.
*E
xp
ec
te
d
R
at
e
in
th
e
A
bs
en
ce
of
S
cr
ee
ni
ng
=
R
es
t
D
K
x
(C
op
en
ha
ge
n,
H
is
to
ric
al
/R
es
t
D
K
H
is
to
ric
al
).
†
S
cr
ee
ni
ng
E
ff
ec
t
=
C
op
en
ha
ge
n
S
tu
dy
/E
xp
ec
te
d
R
at
e
in
th
e
A
bs
en
ce
of
S
cr
ee
ni
ng
.
‡
A
dj
us
te
d
by
5-
ye
ar
ag
e
gr
ou
ps
.
jco.org © 2018 by American Society of Clinical Oncology 2991
Limitations of Screening Effects on Breast Cancer Mortality
Downloaded from ascopubs.org by Royal Library on November 9, 2018 from 130.225.098.216
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
in the analysis will inevitably dilute the measured effect of
screening. When the analysis was restricted to the women who
could have beneﬁted from screening, our data showed a 20%
reduction in breast cancer mortality after invitation to
screening.
Comparison With Other Studies
Studies based on broad age groups showed no marked effect of
screening on breast cancer mortality.6,7 In these studies, it was not
possible to separate breast cancer deaths among women invited to
screening from those among noninvited women. Hence, a sub-
stantial proportion of breast cancer deaths included in these analyses
will be among women who received a breast cancer diagnosis when
they were not eligible for screening (ie, either before the start or after
the end of screening age), as seen also from Dalarna, Sweden.16 In
contrast, in cohort studies with individual records, it is possible to
separate women invited to screening from those not invited, and to
link data from each woman to cancer and cause of death registries.
Then, the analyses could be restricted to women and breast cancer
cases that could potentially have beneﬁted from screening.
The concept of the follow-up model and the evaluation model
were ﬁrst presented by Nystro¨m et al13 in their overview of the
Swedish randomized controlled trials. They found invitation to
screening was associated with a 15% reduction in breast cancer
mortality rate when the follow-up model was used, and a 21%
reduction when using the evaluation model. These results are in
line with ours, indicating the importance of dilution in long-term
follow-up data. Therefore, in later updates, Nystro¨m et al.17
(relative risk, 0.85; 95% CI, 0.73 to 0.98) and Taba´r et al18 (rel-
ative risk, 0.69; 95%CI, 0.56 to 0.84) reported only results from the
evaluation model. In the latter study, less than half of prevented
breast cancer deaths were observed within the ﬁrst 10 years of
follow-up.
In the Swedish analyses,13 the evaluation model used the
person-years from all women from randomization until the end
of the follow-up. In our evaluation model, we restricted the
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person-years after screening age to the women diagnosed with
breast cancer during screening age. This choice was motivated by
the fact that in the evaluation model, only these women were at
risk for dying of breast cancer after end of screening. It should be
noted that this calculation will give high mortality rates in all
groups after the end of screening.
Previously, the Copenhagen screening program was analyzed
using the follow-up model for the ﬁrst 10 years after the program
started. The analysis showed a 25% (95% CI, 11% 37%) reduction
in breast cancer mortality rates after invitation to screening.19 After
a maximum of 23 years of follow-up since the start of the program,
the reduction in breast cancer mortality rate was, as estimated from
the follow-up model, only 11% (95% CI, 2% to 18%). This dif-
ference was a result of the increasing dilution with time from breast
cancer deaths in women who received a diagnosis after screening
age. Hence, a long follow-up after end of screening permits
evaluation of the long-term impact; however, the longer the
postscreening follow-up, the greater the dilution.20 US mortality
data from 2007 to 2011 showed that approximately one-third of
breast cancer deaths in women were attributed to diagnoses after
the age of 70 years.21 Garcı´a-Albe´niz et al22 highlighted the
problems in using observational data in evaluation of cancer
screening outcomes. Their data set was different from the one used
in the current study. Where Garcı´a-Albe´niz et al22 compared
colorectal cancer incidence between persons undergoing and not
undergoing colonoscopy, we compared breast cancer mortality
between populations offered and not offered screening mam-
mography and adjusted for prescreening differences between these
two populations. Thus, we avoided bias from selective participa-
tion and confounding from differences between geographical areas
and/or time periods. Garcı´a-Albe´niz et al22 demonstrated the
importance of never classifying screening status retrospectively;
accordingly, screening status was classiﬁed only prospectively in
our study.
Furthermore, the potential impact of breast cancer
screening on breast cancer mortality rates depends also on the
coverage by examination (the number of participating women
divided by the number of targeted women). A substantial pro-
portion of the targeted population must be screened for
screening to be effective in reducing mortality rates associated
with breast cancer at the population level. In the Copenhagen
program, the coverage by examination at ﬁrst invitation was
between 73% for the ﬁrst targeted birth cohorts and 64% for the
last birth cohorts.23 A drop in coverage was observed with the
increasing invitation number.23 These differences in coverage are
expected to have an impact on the outcome of breast cancer
screening. Then, the true effectiveness of breast cancer screening
might be underestimated.
Limitations and Strengths
Screening advances the date of diagnosis, and slow-growing
and less aggressive tumors, or even nonaggressive tumors in terms
of overdiagnosis, are more likely to be detected by screening, so the
survival advantage of screening detection can be artiﬁcially inﬂated
in the study group as compared with the control subjects. However,
we expected the lead time bias to be limited in our evaluation
model, because the number of deaths resulting from breast cancer
and person-years would be affected by it. Screening, in particular
the ﬁrst screen, may lead to diagnosis of slow-growing tumors. But
this potential time bias was not expected to affect our data set
seriously, because most women attended screening several times,
and all patients with breast cancer were followed up for breast
cancer deaths for a minimum of 10 years. Moreover, the evaluation
model relied on the fact that cases of breast cancer deaths were
previously registered with a diagnosis of breast cancer. This was
veriﬁed for 96% of the breast cancer deaths.
The breast cancer mortality rates in our follow-up model
increased with age, similar to the pattern seen in routine breast
cancer mortality statistics. The data in the follow-up model,
however, do not give a proper presentation of a possible
screening effect because the majority of the breast cancer deaths
after the age of 70 years were diagnosed after the women stopped
being offered screening. This problem was overcome in the
evaluation model by including after the age of 70 years only
breast cancer deaths in women whose cancer was diagnosed
when they were still offered screening. It should be noted,
however, that the breast cancer mortality rates in our evaluation
model increased very rapidly after the age of 70 years. This may
intuitively look strange, but it is explained by the fact that women
diagnosed with breast cancer prior to the age of 70 years are at
a very high risk of dying of breast cancer after the age of 70 years.
This is true for women offered screening and women not offered
screening. The rates in the evaluation model, therefore, should
be used only for internal comparisons between the study group
and three control groups.
The strengths of our study include the use of individual data
with linkage between the exposure and outcome for each woman.
Another strength of our study is that the study group included all
women offered screening and not only those who attended
screening. In this way, we avoided self-selection bias. In addition,
this study took advantage of the use of three control groups;
hence, the expected breast cancer mortality rate in the absence of
screening was estimated by the rate in a nonscreening region,
controlling for regional differences in a prescreening period. Both
region and period were thus controlled for, but it was assumed
that in the absence of screening, the breast cancer mortality rate
changed identically over time in screening and nonscreening
regions. It means no interaction between region and period (ie,
no unsynchronized changes between screening and nonscreening
regions). This assumption was considered realistic because, in
Denmark, diagnostics and treatment of breast cancer have been
organized nationwide since 1977.24 This assumption was further
supported by regional trends in breast cancer mortality rates in
the prescreening period.25 Last, our study was based on a long
follow-up, with a 17-year screening period and 20 years of
postscreening time. All patients with breast cancer were followed
up for breast cancer–related mortality for a minimum of 10 years,
ensuring a long follow-up time even for cases diagnosed at an
early stage. Women screening positive in our study group un-
derwent the same diagnostic procedures as women with symp-
toms of breast cancer.
Our ﬁndings highlight the complexity of evaluating the
long-term impact of screening on breast cancer mortality rates.
We found that screening had a clear, long-term, beneﬁcial
impact of a 20% reduction in breast cancer mortality rate in the
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invited population. Nevertheless, this effect of screening is re-
stricted to breast cancer deaths in women who could potentially
beneﬁt from screening. As women age, a rapidly increasing
proportion of breast cancer deaths occur in women who received
a breast cancer diagnosis after screening age. If this dilution
is not adequately addressed, the effect of screening is inevita-
bly underestimated. Thus, screening is clearly beneﬁcial but,
after screening age, only for a diminishing proportion of
women.
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